Abstract
A DNA vaccine against contagious agalactia was developed for the first time, encoding the P48 of Mycoplasma agalactiae. Specific immune responses elicited in BALB/c mice were evaluated. Both total IgG and IgG1 were detected in mice vaccinated with pVAX1/P48. Proliferation of mononuclear cells of the spleen, levels of gamma interferon, interleukin-12, and interleukin-2 mRNAs were enhanced in immunized animals. Results indicate that pVAX1/P48 vaccination induced both T(h)1 and T(h)2 immune responses. Nucleic acid immunization could be a new strategy against M. agalactiae infections and may be potentially used to develop vaccines for other Mycoplasma diseases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Bacterial Vaccines / administration & dosage
-
Bacterial Vaccines / therapeutic use
-
Cell Line
-
Cytokines / genetics
-
Female
-
Humans
-
Immunity, Active
-
Immunoglobulin G / blood
-
Interferon-Stimulated Gene Factor 3, gamma Subunit / immunology*
-
Kidney / embryology
-
Mice
-
Mice, Inbred BALB C
-
Mycoplasma Infections / immunology*
-
Mycoplasma agalactiae / immunology*
-
RNA, Messenger / genetics
-
Ruminants
-
Spleen / cytology
-
Spleen / immunology
-
Transfection
-
Vaccination / methods
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / therapeutic use*
Substances
-
Bacterial Vaccines
-
Cytokines
-
Immunoglobulin G
-
Interferon-Stimulated Gene Factor 3, gamma Subunit
-
Isgf3g protein, mouse
-
RNA, Messenger
-
Vaccines, DNA